Affibody AB is a Swedish biotechnology company specializing in the development of next-generation biopharmaceuticals. The company leverages its unique proprietary technology platforms to create innovative molecules that offer significant advantages over current targeted approaches. These advantages include excellent toxicity profiles, high tumor uptake, and the ability to reach difficult targets due to superior biodistribution and tissue penetration. Affibody's multi-specific formats enable bi-specific binding and extended half-life, enhancing the efficacy and safety of their treatments.

Affibody serves a diverse range of clients, including pharmaceutical companies, healthcare providers, and research institutions. The company operates in the global biopharmaceutical market, focusing on oncology and inflammatory diseases. Its business model revolves around research and development, followed by licensing its proprietary technology and products to larger pharmaceutical firms. This approach allows Affibody to generate revenue through upfront payments, milestone payments, and royalties on sales of licensed products.

In summary, Affibody AB is at the forefront of biopharmaceutical innovation, utilizing cutting-edge technology to develop effective and safe treatments for challenging medical conditions.

Keywords: biopharmaceuticals, biotechnology, proprietary technology, tumor targeting, biodistribution, oncology, inflammatory diseases, multi-specific formats, licensing, research and development.